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function by echocardiography. After exclusion of pa-
tients in whom Angiotensin Converting Enzyme (ACE)
inhibitors were contraindicated, only seventy-five (58%)
patients received ACE inhibitors of whom, only 7 (9%)
patients received the target dose recommended by the
clinical practice guidelines. There was no documentation
in the records regarding patient counselling about medi-
cation, diet, weight, exercise or smoking. CONCLU-
SION: ACE inhibitors were underused in elderly patients
with heart failure; also achieving the target dose was
poor. This data demonstrated a very low rate of use of
echocardiography in elderly patients with heart failure.
Counseling appeared to be a neglectedaspect of patient
care.
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OBJECTIVES: Prophylactic anticoagulants, such as low
molecular weight heparin, to prevent thrombosis in hos-
pitalized medical patients has been recommended in clini-
cal guidelines, however the impact on quality adjusted
life years (QALYs) is unclear. This pilot study evaluated
enoxaparin for this indication among elderly (age 59)
hospitalized medical patients. METHODS: Patients were
randomized to receive subcutaneous injections of enox-
aparin 30 mg or placebo daily. Patients who had medical
indications for anticoagulation (e.g., myocardial infarc-
tion, history of thrombosis) were excluded. QALYs were
measured for the period of 30 to 90 days post random-
ization, using the Health Utilities Index(HUI). At 30 and
90 days, 51 and 40 patients in the active group com-
pleted the HUI versus 49 and 36 patients in the placebo
group, respectively. Surveys were received at both time
points among 40 enoxaparin and 21 placebo patients.
QALYs and changes in domain scores were analyzed
over the time between the two surveys. Data were ana-
lyzed using t-tests. RESULTS: Significantly more QALYs
were gained (p  .007)among enoxaparin treated pa-
tients. The mean QALY values were 0.005  0.015 vs
0.008  0.015. The change in the HUI, Mark III do-
main score for ambulation approached significance (p 
0.053. The mean values were 0.012  0.098 for enox-
aparin versus 0.027  0.056 for placebo. A significant
change in the HUI, Mark II domain score for mobility
was found (p  0.017, mean values 0.015  0.064 ver-
sus 0.022  0.050). CONCLUSION: Among medical
patients prophylactic treatment with enoxaparin was as-
sociated with increased QALYs.
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OBJECTIVES: With over one-third of the population
considered to be obese, obesity has reached epidemic pro-
portions in the US The direct costs associated with obe-
sity are currently estimated at about $238 billion. As the
underlying cause of various chronic diseases, obesity neg-
atively impacts quality of life due to impaired physical
and mental well being and reduced daily functions. The
objective of this study is to evaluate the relationship be-
tween obesity and health-related quality of life using the
Centers for Disease Control and Prevention’s (CDC) Be-
havioral Risk Factor Surveillance System (BRFSS) data.
METHODS: The BRFSS is an ongoing, state-based, ran-
dom digit dialed telephone survey of the civilian, non-
institutionalized population aged 3 18 years conducted by
CDC. Data from sixteen states that collected information
on health status (4 items), HRQoL (10 items), and demo-
graphic characteristics including weight and height from
50,454 participants in 1998 were utilized for the analy-
sis. Participants who had a Body Mass Index (BMI) 3 30
were defined as obese. Prevalence of obesity by demo-
graphics and disease presence was determined, as were
corresponding HRQoL scores. RESULTS: On the basis
of BMI, 31.9% of the respondents were identified as
obese. Obesity was higher in males as compared to fe-
males and higher among African-Americans and Hispan-
ics as compared to whites. Obesity increased with age but
decreased as income and education increased. Obese re-
spondents reported poorer health status. Impact of obe-
sity on HRQoL due to reduced physical and mental func-
tioning in the presence of no health problems, as well
as in presence of self-reported major health problems
such as arthritis, cardiovascular disease, diabetes, cancer,
depression, and pulmonary disease is discussed. CON-
CLUSIONS: Health related quality of life is significantly
affected due to obesity and should be an important con-
sideration in the treatment of obesity. It also has impor-
tant implications in case of illnesses that have obesity as
an underlying cause.
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OBJECTIVE: To determine the impact of outpatient an-
ticoagulant/antiplatelet therapy on treatment charges in
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patients receiving coronary artery stents in a managed
care population. METHODS: Patients were selected
from the PharMetrics Integrated Outcomes Database
who underwent coronary angioplasty and stent insertion
between January 1 and June 30, 1999 and who had at
least 6 months of continuous enrollment in their health
plan following the beginning of the treatment episode.
Patients were grouped according to whether they received
outpatient anticoagulant/antiplatelet prescription drug
therapy following their stent procedure. Patients were
also stratified by history of acute myocardial infarction
(AMI) and presence of comorbid conditions (diabetes
and hypertension). Total charges associated with the
stenting treatment episode (up to 6 months following the
procedure) were assessed. RESULTS: 2,713 patients re-
ceiving anticoagulant/antiplatelet therapy and 438 un-
treated patients met all selection criteria. The two treat-
ment groups were similar in age (58.6 vs. 58.0 years
respectively, p  0.322) and in the frequency of AMI
(37.7% vs. 37.9% respectively, p  0.939) and of one or
more comorbidities (73.3% vs. 71.5% respectively, p 
0.427). Mean charges over the study period for the anti-
coagulant/antiplatelet cohort exceeded those in the un-
treated cohort by $4,748 (p  0.014). Pharmacy charges
accounted for only $297 of this excess ($660 vs. $363,
respectively). Most of the difference between treatment
groups was in the medical costs of interventional cardiol-
ogy. CONCLUSION: Among coronary stent recipients,
the mean charge for a 6-month period in patients who
also received anticoagulant/antiplatelet prescription drug
therapy was 14% higher than in the untreated cohort,
due mainly to higher medical charges. It is possible that
untreated patients were less severely ill or had a favorable
risk profile. Further investigation of these data will exam-
ine this issue.
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OBJECTIVE: To estimate the cost-effectiveness of enox-
aparin (1 mg/kg s.c. bid) vs unfractionated heparin
(UFH) (i.v. bolus and constant infusion adjusted to main-
tain a therapeutic APTT) in acute coronary syndrome
(ACS) patients from a Polish hospital perspective. The in-
tention was to facilitate the decision-making process in
selecting the most cost-effective treatment for ACS.
METHODS: Decision model was used to quantify costs
and effectiveness of alternative treatments. Published re-
sults from ESSENCE study were used to estimate the
probability for clinical end-points (death, MI, recurrent
angina) at 30 days. Probabilities of patients receiving
revascularisation procedures were obtained from the
GRACE registry (961 patients at 6 centres in Poland).
The analysis assessed only direct medical costs resulting
from the treatment of events comprising the composite
end-point, revascularisation procedures, enoxaparin and
UFH therapy, related medications. The costs were deter-
mined from actual resource consumption on a patient-
specific basis (6 months observational study) and esti-
mated using Polish data on unit costs. One- and two-way
sensitivity analysis and treshold analysis were performed.
RESULTS: At 30 days 19,8% of patients receiving enox-
aparin compared with 23,3% of patients receiving UFH
reached one event of the composite end-point (p  0,02).
The average costs (in PLN, 1 USD  4 PLN) were 1085
per patient receiving enoxaparin compared with 1097 per
patient receiving UFH. Therefore for every 29 patients
treated, enoxaparin therapy would not only avoid one
event of the composite end-point, it would also save 348
PLN. The threshold analysis revealed, that enoxaparin
would lose the dominance, when cost of enoxaparin ther-
apy would increase by 30%, cost of UFH—decrease by
47%, probability end-point in enoxaparin arm increase
to 0.22 or in UFH arm decrease to 0.2. CONCLUSION:
Since enoxaparin resulted in a better effect at a lower
cost, this antithrombotic strategy was considered to be
dominant for Polish patients with ACS.
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OBJECTIVE: The objective of this study was to examine
the role of quality of life (QOL) and patient preference as
predictors for resource utilization among patients with
heart failure (HF). METHODS: QOL, patient preference,
resource utilization, and survival are being assessed in 94
patients with HF managed in an urban HF specialty
clinic. QOL is measured using a disease-specific question-
naire, the Kansas City Cardiomyopathy Questionnaire
(KCCQ) and a generic questionnaire, the Short Form 12
(SF-12), at baseline, 3 months, and 6 months. Patient
preference is measured using standard gamble technique
at baseline. Resource use including hospitalization, ER
visits, procedures, and outpatient visits are captured by
patient interview and verified by clinic and hospital
records. Health care costs are derived from clinic cost
data, University Health System Consortium database,
and literature. RESULTS: To date, 81 patients have com-
pleted 3 months follow-up (mean age 49.9  14.0 years;
69% African American; 53% male; NYHA class I  15,
